Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
Instil Bio, Inc.
TIL · SEC Filings
website
17
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic oppo...
Price
6.47
Market Cap
44.45 M
Float
3.58 M
Country
US
Sector
Healthcare
Exchange
NASDAQ
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about TIL
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
Instil Bio, Inc.
TIL · SEC Filings
3.58 M
Float
6.47
Price
44.45 M
Market Cap
Financials
TYPE
HEADLINE
FILED AT
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 13, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 15, 2026
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 27, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 13, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 13, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 13, 2025
News
TYPE
HEADLINE
FILED AT
8-K
Instil Bio Reports Second Quarter 2026 Financial Results and Corporate Update
Aug 13, 2026
8-K
Instil Bio, Inc. Announces Results of 2026 Annual Meeting of Stockholders
Jun 11, 2026
8-K
Instil Bio Reports Q1 2026 Financial Results and Strategic Update
May 15, 2026
8-K
Instil Bio, Inc. Announces Change of Independent Registered Public Accounting Firm
Apr 3, 2026
8-K
Instil Bio Reports 2025 Financial Results and Strategic Shift Toward External Innovation
Mar 27, 2026
8-K
Instil Bio Terminates License and Collaboration Agreement with ImmuneOnco
Jan 6, 2026
Prospectus
TYPE
HEADLINE
FILED AT
424B5
March 2025 ATM
Mar 31, 2025
424B4
16,000,000 Shares-
Mar 22, 2021
Registrations
TYPE
HEADLINE
FILED AT
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Mar 27, 2026
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Mar 4, 2025
S-3
SHELF | Offering amount: $200,000,000.00 EFFECTIVE
Nov 13, 2024
S-8
Registration
Mar 21, 2024
S-3ASR
Common Stock
Apr 1, 2022
S-8
Common Stock
Apr 20, 2021
Proxies
TYPE
HEADLINE
FILED AT
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 24, 2026
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 24, 2026
DEFR14A
Form DEFR14A - Revised definitive proxy soliciting materials
May 2, 2025
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 14, 2025
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 14, 2025
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 26, 2024
Ownerships
TYPE
HEADLINE
FILED AT
4
McGaughy R Kent Jr (Reporting)
Jun 12, 2026
4
Matcham George (Reporting)
Jun 12, 2026
4
Gibson Neil W (Reporting)
Jun 12, 2026
4
Binder Gwendolyn (Reporting)
Jun 12, 2026
SCHEDULE 13G/A
BML Investment Partners, L.P. (Filed by)
Feb 9, 2026
4
Laumas Sandeep (Reporting)
Sep 12, 2025
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
EFFECT
Form EFFECT - Notice of Effectiveness
Nov 22, 2024
CORRESP
Form CORRESP - Correspondence
Nov 19, 2024
LETTER
Form UPLOAD - SEC-generated letter
Nov 19, 2024
EFFECT
Form EFFECT - Notice of Effectiveness
Mar 19, 2021
CORRESP
Form CORRESP - Correspondence
Mar 16, 2021
CORRESP
Form CORRESP - Correspondence
Mar 16, 2021
